Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
4 May 2022
Pipeline Review – View full story
Amphista lands potentially rich deals with Merck, BMS
4 May 2022
BioWorld – View full story
BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform
4 May 2022
BioSpace – View full story
Dundee University spin-out lands deals worth up to £1.6 billion
4 May 2022
The Courier – View full story
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships
4 May 2022
FierceBiotech – View full story
An upstart protein degradation contender adds Merck KGaA and Bristol Myers to its list of Big Pharma backers
4 May 2022
Endpoints News – View full story
Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
4 May 2022
Drug Development & Delivery – View full story
BMS inks protein degrader alliance with Amphista
4 May 2022
FirstWord Pharma – View full story
Amphista Therapeutics and Bristol Myers Squibb partner for development of protein degradation therapeutics
4 May 2022
Pharmafile – View full story
Eli Lilly, Novartis back a biotech startup boasting ‘best of both worlds’ protein degraders
17 March 2021
Endpoints – View full story
